CTLA4 and metastatic melanoma: MDX-CTLA-4 administration can suppress metastasis to the CNS, lungs, abdomen, and soft tissues through the induction of extensive tumor necrosis and CD8+ T cell infiltration in patients suffering from metastatic melanoma, which previously vaccinated with irradiated cancerous cells engineered to form granulocyte–macrophage colony-stimulating factor [78].